Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00421122 | Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD | PHASE3 | COMPLETED | 315 | — | — | Sep 1, 2006 | Nov 1, 2007 | Mar 27, 2009 | 8 | China |
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Bricasol® |
| 2 | EXPERIMENTAL | Bricasol® + Pulmicort® |
| 3 | EXPERIMENTAL | Bricasol® + Symbicort® |
| Name | Type | Description |
|---|---|---|
| budesonide/formoterol (Symbicort) | DRUG | inhalation therapy |
| budesonide (Pulmicort) | DRUG | inhalation |
| terbutaline sulfate (Bricasol) | DRUG | inhalation therapy |
Inclusion Criteria: * Signed and dated inform consent * Out-patient, clinical diagnosis of COPD * Men or women at the age of 40 or over Exclusion Criteria: * A history of asthma * Seasonal allergic rhinitis before 40 years of age * Patients with significant or unstable ischemic heart disease, arr...